

No. 209

17 March 2010


MEDICINES AND RELATED SUBSTANCES ACT, 1965**ANNUAL REVIEW OF THE SINGLE EXIT PRICES OF MEDICINES AND
SCHEDULED SUBSTANCES FOR 2011**

The Minister of Health intends, in terms of Regulation 8(1) of the Regulations Relating to the Transparent Pricing System for Medicines and Scheduled Substances published under the Medicines and Related Substances Act, 1965 (Act 101 of 1965), to review the extent to which the Single Exit Price (SEP) of medicines and scheduled substances may be increased for the year 2011.

Interested parties, in their submissions, are requested to consider the following:

1. Should CPI be replaced with PPI for calculating the domestic component, given that the SEP changes are only meant to accommodate changes in production costs;
2. Whether the international component should be removed entirely in favour of a published indicator which already embodies exchange rate changes, such as the PPI for pharmaceuticals produced for domestic consumption.
3. Are the weights in the previously used formula applicable to the domestic and international components truly reflective of changes in the cost structure of pharmaceutical manufacturers;
4. Should the international component incorporate a basket of countries;

Interested parties are invited to submit any substantiated submissions on the proposed review of the single exit price to the Director General of Health, Private Bag X828, Pretoria, 0001, (for the attention of the Director: Pharmaceutical Economic Evaluations) within three months of the date of the publication of this notice.



Dr A MOTSOLEDI, MP
MINISTER OF HEALTH
DATE: 12/03/2010